Member Info for daveycaferacer

https://www.globenewswire.com/news-release/2019/11/23/1951641/0/en/Chi-Med-Highlights-Oral-Presentations-at-2019-ESMO-Asia-Annual-Meeting.html

includes links to Abstracts

ESMO Asia this weekend:-

LONDON, Nov. 23, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will share analyses from two clinical studies of savolitinib and fruquintinib at the fifth European Society for Medical Oncology Asia Congress (“ESMO Asia”) on November 22 to 24, 2019 in Singapore.

I agree, I was expecting it by now but haven't seen coverage of this years list, that said, it is simply scheduled for Q4

https://www.standard.co.uk/business/hutchison-china-meditech-looks-like-a-healthy-bet-in-its-major-drugs-push-a4152891.html

This article is 6 months old but may be useful for any new Investors who have not seen it

Not directly related to Chi-Med but there's an intriguing Webinar entitled "How Chinese Biotechs Are Fueling the Oncology Space" with Brad Loncar as a panelist

http://portal.emailnetworks.com/vm2/7045834e974cf8be/25277/2496817374bec140e3e76a0e50d35c2b

Why are people dumping this, were they waiting until it went ex-divi?

There is now a header page on the Company's website together with a link to the Squawk Box Page https://www.chi-med.com/

Very high volumes on NASDAQ in the last few days, hopefully we can’t get back to the share price of where we we a couple of years ago

Elunate NRDL news due any day now

https://www.cnbc.com/video/2019/11/15/chi-med-is-looking-to-launch-a-new-cancer-drug-in-china.html?__source=sharebar|twitter&par=sharebar

Worth following the Company on Twitter for those that way inclined! @HChiMed

Great update session by our CEO today at the short DB Investor event, I particularly picked up on these aspects in response to some questions submitted via the DB portal

1. There is still an appetite and the Company does see value in a HK listing, once the share price recovers after the CKHH deconsolidation

2. NRDL Elunate update could come very shortly (within the next couple of weeks)

3. The Company is confident that the excellent and material pipeline progression should see the share price recover back to previous levels

4. Savo is well on track for NDA submission in around March 2020 in China for Exon 14 del

Starts 08:30 EST, 13:30 GMT

Live Web Event:
dbVIC - Deutsche Bank Virtual Investor Conference
November 13 and 14, 2019

To register, please use the following link: www.adr.db.com/dbvic

Nice article from Monday's WSJ on China’s Drug Market

https://www.wsj.com/articles/chinas-drug-market-is-opening-up-11573468202?reflink=share_mobilewebshare

I found this development particularly interesting:-
"last week, AstraZeneca said it is setting up a $1 billion fund to invest in biotechnology startups in China"

Trinity Delta have issued an updated Research Note yesterday

https://www.trinitydelta.org/research-notes/acceptance-of-surufatintib-china-nda-in-epnet/

absolutely Jatw, a home market listing will be a good thing

Plenty of conferences and events coming up

London: Monday, November 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the following conferences:

• Deutsche Bank Depositary Receipts Virtual Investor Conference (dbVIC) webcast on Wednesday, November 13, 2019 at 8:30 am (EST) / 1:30 pm (GMT) / 9:30 pm (China Time);

• BioCentury & Bayhelix China Healthcare Summit on Wednesday, November 20, 2019 at 1:30 pm (China Time) in Shanghai; and

• Presentation at Piper Jaffray Annual Healthcare Conference on Tuesday, December 3, 2019 at 8:50 am (EST), and investor meetings on Tuesday, December 3, 2019 in New York.

In addition, members of the management team will attend the following investor conferences:

• Presentation at Jefferies University Specialist Speakers Summit on China Disruption & Innovation on Friday, November 15, 2019 in Hong Kong;

• Investor meetings at Jefferies London Healthcare Conference on Wednesday, November 20, 2019 and Thursday, November 21, 2019 in London;

• Investor meetings at Morgan Stanley Annual Asia Pacific Summit on Thursday, November 21, 2019 in Singapore; and

• Presentation at Goldman Sachs Asia Pacific Healthcare Forum on Monday, November 25, 2019 at 11:30 am (Hong Kong Time), and investor meetings on Monday, November 25, 2019 and Tuesday, November 26, 2019 in Hong Kong.

Further information are available at www.chi-med.com in the Shareholder Information section under “Events, Circulars & Forms.”

I agree amones, I assumed the HK IPO would open up Chi-Med to a wider pool of Investors, especially in Asia so let's hop we see that resurrected at some point

surufatinib NDA acceptance announced today is wonderful news - $169m forecast peak revenues in China for NET alone

Our CEO will be presenting at another DB Investor event on November 13th:-

To register, please use the following link: www.adr.db.com/dbvic

Pre-registration is suggested to save time.

November 13th Agenda (US Eastern Standard Time):

8:30 AM: Hutchison China MediTech (LONDON AIM: HCM,NASDAQ: HCM)

I agree with the bulk of this analysis posted on Seeking Alpha on Tuesday

https://seekingalpha.com/instablog/32746315-michael-england/5371294-hcm-riding-wave